Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Oil Prices Rise as Hormuz Reopening Remains Uncertain 
Trump Election Order Blocked Again as Appeals Court Rejects Mail-In Voting Push in 23 States 
S&P 500, Nasdaq Slip as Oil Jumps on Iran Tensions 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
US Stock Futures Flat as Iran Strait of Hormuz Demands Fuel Oil Concerns 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Gold Prices Hold Near Seven-Week High as Markets Await U.S. Inflation Data 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
DOJ Rescinds Anti-Weaponization Fund Ahead of Todd Blanche Senate Confirmation Vote 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Japan Posts First Current Account Deficit in 17 Months as Dividend Payments Surge 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
US Supreme Court Lets $655.5 Million Judgment Against Palestinian Authorities Stand During Appeal 
3 clinical-grade skincare creams you really shouldn’t buy online 
Airbus Joins Air India A320 Altitude Drop Probe 
The US Food and Drug Administration (FDA) is planning to regulate the use of the cannabis compound CBD in food and supplements after weighing the evidence on the compound's safety.
The FDA will decide whether regulating legal cannabis will require new agency rules or new legislation from Congress.
Cannabis products, excluding Epidiolex, are illegal at the federal level in the US, although some states allow their use.
According to Patrick Cournoyer, who heads the FDA office developing the agency's cannabis strategy, the FDA will ascertain if CBD can be safely eaten every day for a long period or during pregnancy amid concerns about future fertility.
.
